Leveraging Morphological Profiling for Mechanistic Elucidation of Metal-Based Anticancer Compounds
Brian J Park1, Shane Harrypersad1, Aryan Houshmand2
1Bold Therapeutics Inc, 170-422 Richards St, Vancouver, British Columbia V6B 2Z4, Canada.
JACS Au
|July 30, 2026
Summary
Morphological profiling of metal compounds reveals their mechanisms of action without predefined targets. This approach identifies novel metallotherapeutics, like a ruthenium compound targeting cancer cell mitochondria.
Area of Science:
- Metallomics and Medicinal Chemistry
- Cellular Imaging and Phenotypic Screening
- Drug Discovery and Development
Background:
- Metallotherapeutics offer promise but face challenges in understanding complex reactivity and molecular targets.
- Phenotypic drug profiling has advanced anticancer drug development, yet its application to metallodrugs is limited.
- Elucidating mechanisms of action for metal-based drugs is crucial for rational development.
Purpose of the Study:
- To demonstrate morphological profiling as a method for discovering metallotherapeutics.
- To elucidate mechanisms of action for metal-containing compounds without predefined targets.
- To identify novel metallodrug candidates with anticancer potential.
Main Methods:
- Utilized morphological profiling on a diverse library of metal-containing compounds.
- Validated the strategy with clinically approved anticancer therapeutics (oxaliplatin, cisplatin, carboplatin, BOLD-100).
- Combined cytotoxicity, selectivity assessments, and morphological profiling to identify novel compound series.
Main Results:
- Morphological profiling distinguished mechanistic differences among established platinum-based drugs and a ruthenium compound.
- Identified a novel ruthenium 2-(2-pyridyl)-benzimidazole series with anticancer activity.
- Observed mitochondrial morphology changes, increased reactive oxygen species, and mitochondrial membrane depolarization in cancer cells treated with the novel compounds.
Conclusions:
- Morphological profiling is effective for target-agnostic metallodrug discovery and mechanism elucidation.
- This approach accelerates the identification of promising metal-containing therapeutics.
- Facilitates rational development strategies for metallotherapeutics, overcoming existing challenges.
Related Concept Videos
01:23Properties of Organometallic Compounds
Organometallic compounds are compounds that contain a carbon–metal bond. Carbon belongs to an organyl group like alkyl, aryl, allyl, or benzyl groups. The metal can be from Group I or Group II of the periodic table, a transition metal, or a semimetal.
00:56Extraction: Advanced Methods
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is formed in...
02:51Metal-Ligand Bonds
The hemoglobin in the blood, the chlorophyll in green plants, vitamin B-12, and the catalyst used in the manufacture of polyethylene all contain coordination compounds. Ions of the metals, especially the transition metals, are likely to form complexes.
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
01:33Proteomics
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...